Recently, the drug Crizotinib (Pfizer’s Xalkori) successfully obtained FDA approval as a treatment for patients with NSCLC with MET exon 14 skipping which occurs in approximately 3% of NSCLC tumours and ROS 1/anaplastic lymphoma kinase-positive resistant systemic anaplastic large cell lymphoma (ROS-1/ALK-ALCL) [111]. The gene discussed is ROS1; the disease is anaplastic large cell lymphoma.